Key Takeaways:

• Arey secured a Series A investment led by Unilever Ventures.
• Arey’s products slow and reverse grey hair with science-backed topicals and supplements.
• Arey's first clinical trial will be published in the Journal of Drugs in Dermatology.

The fresh capital will support Arey’s long-term growth strategy.

WHO: Founded in 2020 by CEO Allison Conrad and trichologist and celebrity hairstylist Jay Small, Arey created a new category in haircare and is leading innovation with products formulated to preserve your future hair, setting a new standard for aging haircare with solutions that simply didn’t exist before: rooted in science, validated by clinical trials, and proven to deliver results, giving people control over one of the most universal signs of aging. From inception, Arey has focused on hair longevity, believing that scalp and hair aging can be addressed at the biological level through proactive care, before the visible signs take hold.

Arey has clinically proven that grey hair can be slowed and repigmented through their System (supplement and serum combination). The brand followed the gold standard in clinical studies, conducting a randomized, double-blind, placebo-controlled, third-party study, in which 88% of those on The System had fewer or no new grey hairs. Participants also reported 3x thicker, fuller, shinier hair versus placebo. The full results of the trial have been accepted for publication in the November issue of the Journal of Drugs in Dermatology, a leading peer-reviewed academic medical journal.

WHY: The investment will support Arey’s long-term growth strategy: new product development, ongoing clinical research, larger retail expansion, new...